Schizophrenia News and Research

Latest Schizophrenia News and Research

Intense visual stimulation renders nerve cells more receptive to subsequent learning

Dr. Ed Ruthazer is a mapmaker but, his landscape is the developing brain - specifically the neuronal circuitry, which is the network of connections between nerve cells. His research at The Montreal Neurological Institute and Hospital - The Neuro at McGill University, reveals the brain as a dynamic landscape where connections between nerves are plastic, changing and adapting to the demands of the environment.

21 Jul 2011

Common cancer drug alleviates symptoms associated with schizophrenia

Researchers have revealed the molecular pathway that is affected during the onset of schizophrenia and successfully alleviated symptoms of the illness in mice, using a commonly used cancer drug.

21 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011

Simple lifestyle changes could prevent half of all Alzheimer's disease cases

Over half of all Alzheimer's disease cases could potentially be prevented through lifestyle changes and treatment or prevention of chronic medical conditions, according to a study led by Deborah Barnes, PhD, a mental health researcher at the San Francisco VA Medical Center.

19 Jul 2011

Ultrasound can detect risk of psychiatric disorders in premature infants

Infants born prematurely are at risk for injuries to the white and gray matter of the brain that affect cortical development and neural connectivity. Certain forms of these injuries can be detected in the neonatal period using ultrasound, according to Columbia University Medical Center researchers.

15 Jul 2011

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."

15 Jul 2011

Longer looks: Penalties for doctors who keep patients waiting

When she makes a doctor's appointment, Cherie Kerr makes it clear that she better not be kept waiting long. She said she usually tries to schedule the first appointment of the day, or the first one after lunch. But if the doctor is going to be late, she insists the staff give her a call -- lest the office be billed for her time in the waiting room.

15 Jul 2011

Young investigators to receive Brain & Behavior Research Foundation awards

Brain & Behavior Research Foundation will honor five outstanding researchers at the Annual Klerman and Freedman Awards event in New York City.

15 Jul 2011

HIV patients with mental illness can benefit from APRN care management

In a four-year study, researchers at the University of Pennsylvania have found that assigning adults with serious mental health illness who are HIV positive to the care of advanced practice nurses (APRN) to help navigate the health care system and maintain adherence to drug regimens reduced depression and improved their overall physical health, indicating that healthcare policy should be revamped to provide this support.

12 Jul 2011

Study may help explain why antipsychotic drugs can promote overeating, weight gain

Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, may explain why some antipsychotic drugs can promote overeating, weight gain, and insulin resistance.

12 Jul 2011

Scientists identify de novo mutations linked to schizophrenia

De novo mutations - genetic errors that are present in patients but not in their parents - are more frequent in schizophrenic patients than in normal individuals, according to an international group of scientists led by Dr. Guy A. Rouleau of the University of Montreal and CHU Sainte-Justine Hospital.

11 Jul 2011

Global research initiative to improve health care for people with MNS disorders

Mental health experts are calling for a greater world focus on improving access to care and treatment for mental, neurological, and substance use (MNS) disorders, as well as increasing discoveries in research that will enable this goal to be met.

7 Jul 2011

Individuals with anorexia nervosa have elevated mortality rate

Individuals who have eating disorders have an elevated mortality rate, especially those with anorexia nervosa (AN), according to a meta-analysis of previous studies, reported in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

5 Jul 2011

Nicotine receptors play crucial role in social interaction

If you think nicotine receptors are only important to smokers trying to kick the tobacco habit, think again. New research published in the FASEB Journal (http://www.fasebj.org) suggests that these receptors also play an important role in social interaction and the ability to choose between competing motivations.

1 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

Viewpoints: Calif.'s budget, Supreme Court drug rulings, the Avastin debate

The budget is not realistic, counting on fantastical revenue projections as well as a redevelopment gambit that's likely to be blocked in court. It makes deep cuts in state programs that will have unwelcome repercussions in years to come. And if the revenue projections prove to be as overly optimistic as they seem, there will be more damaging cuts to education, child care and health services. Nevertheless, it's a more earnest effort to clean up the state's budget mess than Sacramento has seen in a decade or more.

30 Jun 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

Synthetic cannabis ban in NSW from 1st of July

Kronic and other named synthetic drugs that induce effects similar to cannabis will be banned in NSW from July 1. NSW Mental Health Minister Kevin Humphries announced this saying use of the products sold online and at retail outlets have led to warnings from doctors. He added that the state government will ban the products under existing legislation.

28 Jun 2011

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros Corporation today reported that it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells.

27 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011